Comparable stake leader
FMR LLC
SEC ownership of TransMedics Group, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001756262.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
15 Jun 2026
- Public ticker
- TMDX on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
FMR LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
FMR LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
15 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001756262
- Issuer location
- Andover, MA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of TransMedics Group, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
15 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 15%
13D/G row: FMR LLC
Showing 1-8 of 50 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 15%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
15%
BlackRock, Inc.
15%
VANGUARD PORTFOLIO MANAGEMENT LLC
5.7%
VANGUARD CAPITAL MANAGEMENT LLC
5.1%
Thomas J. Gunderson
0.05%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
Company
|
15%
from 13D/G
|
$506,617,469
5,096,243 shares
|
— | 31 Mar 2026 |
| BlackRock, Inc. |
13D/G
13F
Company
|
15%
|
$664,054,661
4,955,262 shares
|
$0 | 30 Jun 2025 |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13D/G
13F
Vanguard Portfolio Management · Company
|
5.7%
|
$193,791,842
1,949,420 shares
|
$0 | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
Vanguard Capital Management · Company
|
5.1%
|
$172,688,789
1,737,137 shares
|
$0 | 31 Mar 2026 |
| Thomas J. Gunderson |
3/4/5
Director
|
0.05%
|
$1,249,148
16,642 shares
|
-$722,377 | 15 Jun 2026 |
| Edward M. Basile |
3/4/5
Director
|
0.02%
|
$575,385
5,788 shares
|
-$540,324 | 20 May 2026 |
| Stephanie Lovell |
3/4/5
Director
|
0.02%
|
$575,385
5,788 shares
|
-$178,497 | 20 May 2026 |
| STATE STREET CORP |
13F
Company
|
3.8%
|
$131,169,407
1,319,479 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$3,872,664.
Buys
$1,000,350
Insiders: 1
Sells
$4,873,014
Insiders: 7
Net
-$3,872,664
Shares: -30,116
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 8,775
Shares: 38,891
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 9,624 | $0 | $722,377 | -$722,377 |
| 3-6 | 0 | 16,205 | $0 | $2,353,002 | -$2,353,002 |
| 6-9 | 8,775 | 8,920 | $1,000,350 | $1,257,310 | -$256,960 |
| 9-12 | 0 | 4,142 | $0 | $540,324 | -$540,324 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 20 reporting-owner rows connected to TransMedics Group, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
20
Largest Forms 3/4/5 holder
Waleed H. Hassanein
Net 12M change
-$3,872,664
Latest report
10 Jul 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Waleed H. Hassanein | President & CEO, Director | $44,243,026 | +$1,000,350 | +2.3% | Median | 10 Jul 2026 |
| Edwin Kania | Director | $30,804,574 | Mixed | 20 May 2026 | ||
| James R. Tobin | Director | $17,906,424 | Mixed | 20 May 2026 | ||
| Stephen Gordon | Chief Financial Officer | $2,895,173 | Filing P/S | 03 Jun 2024 | ||
| Nicholas Corcoran | SVP of Supply Chain and Operations | $2,760,315 | -$412,630 | -13% | Median | 10 Jul 2026 |
| Tamer I. Khayal | Chief Commercial Officer | $2,754,690 | Filing P/S | 03 Mar 2025 | ||
| Giovanni Cecere | Chief Commercial Officer | $2,648,351 | Mixed | 18 Feb 2026 | ||
| Gerardo Hernandez | Chief Financial Officer | $2,121,148 | -$1,245,832 | -37% | Median | 10 Jul 2026 |
| Miriam Provost | VP, Global Regulatory Affairs | $2,103,421 | Mixed | 13 Dec 2023 | ||
| Anil P. Ranganath | Senior Vice President, General Counsel and Secretary | $1,821,219 | -$555,860 | -23% | Filing P/S | 02 Mar 2026 |
| Matthew S. Forsyth | Senior Vice President, General Counsel and Secretary | $1,531,808 | Mixed | 19 May 2026 | ||
| David Weill | Director | $1,496,716 | -$1,217,494 | -45% | Mixed | 20 May 2026 |
| John F. Sullivan | VP of Quality & Engineering | $1,285,855 | Mixed | 30 Aug 2021 | ||
| John F. Carey | VP of Operations | $1,272,071 | Mixed | 01 Feb 2023 | ||
| Thomas J. Gunderson | Director | $1,249,148 | -$722,377 | -37% | Filing P/S | 15 Jun 2026 |
| Merilee Raines | Director | $693,981 | Mixed | 20 May 2026 | ||
| Stephanie Lovell | Director | $575,385 | -$178,497 | -24% | Mixed | 20 May 2026 |
| Edward M. Basile | Director | $575,385 | -$540,324 | -48% | Mixed | 20 May 2026 |
| Laura Damme | VP, Clinical Affairs | $512,162 | Mixed | 20 Feb 2023 | ||
| Rakesh P. Godhani | Chief Digital Officer | Mixed | 04 Aug 2021 |
Recent insider transactions for TransMedics Group, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Nicholas Corcoran | TMDX | Common Stock | Award | 39.3% | 11,727 | 41,558 | 10 Jul 2026 | Direct | ||
| Nicholas Corcoran | TMDX | Stock Option (Right to Buy) | Award | 17,784 | 17,784 | 10 Jul 2026 | Direct | |||
| Gerardo Hernandez | TMDX | Common Stock | Award | 117.4% | 17,246 | 31,935 | 10 Jul 2026 | Direct | ||
| Gerardo Hernandez | TMDX | Stock Option (Right to Buy) | Award | 26,153 | 26,153 | 10 Jul 2026 | Direct | |||
| Waleed H. Hassanein | TMDX | Common Stock | Award | 40.9% | 49,669 | 171,093 | 10 Jul 2026 | Direct | ||
| Waleed H. Hassanein | TMDX | Stock Option (Right to Buy) | Award | 112,984 | 112,984 | 10 Jul 2026 | Direct | |||
| Thomas J. Gunderson | TMDX | Common Stock | Sale | -36.6% | $722,377 | $75.06 | -9,624 | 16,642 | 15 Jun 2026 | Direct |
| Thomas J. Gunderson | TMDX | Common Stock | Options Exercise | 276.2% | 19,285 | 26,266 | 15 Jun 2026 | Direct | ||
| Thomas J. Gunderson | TMDX | Stock Option (Right to Buy) | Options Exercise | -100% | -19,285 | 0 | 15 Jun 2026 | Direct | ||
| Stephanie Lovell | TMDX | Common Stock | Award | 102% | 2,922 | 5,788 | 20 May 2026 | Direct | ||
| David Weill | TMDX | Common Stock | Award | 24.1% | 2,922 | 15,056 | 20 May 2026 | Direct | ||
| Merilee Raines | TMDX | Common Stock | Award | 72% | 2,922 | 6,981 | 20 May 2026 | Direct | ||
| Thomas J. Gunderson | TMDX | Common Stock | Award | 72% | 2,922 | 6,981 | 20 May 2026 | Direct | ||
| Edward M. Basile | TMDX | Common Stock | Award | 102% | 2,922 | 5,788 | 20 May 2026 | Direct | ||
| James R. Tobin | TMDX | Common Stock | Award | 72% | 2,922 | 6,981 | 20 May 2026 | Direct | ||
| Edwin M. Kania Jr. | TMDX | Common Stock | Award | 1.12% | 2,922 | 263,732 | 20 May 2026 | Direct | ||
| Matthew S. Forsyth | TMDX | Common Stock | Award | 15,409 | 15,409 | 19 May 2026 | Direct | |||
| Matthew S. Forsyth | TMDX | Stock Option (Right to Buy) | Award | 23,171 | 23,171 | 19 May 2026 | Direct | |||
| Stephanie Lovell | TMDX | Common Stock | Sale | -29.4% | $178,497 | $149.62 | -1,193 | 2,866 | 04 Mar 2026 | Direct |
| David Weill | TMDX | Common Stock | Sale | -22.7% | $524,294 | $146.82 | -3,571 | 12,134 | 04 Mar 2026 | Direct |
| David Weill | TMDX | Common Stock | Options Exercise | 29.4% | 3,571 | 15,705 | 04 Mar 2026 | Direct | ||
| David Weill | TMDX | Stock Option (Right to Buy) | Options Exercise | -71.4% | -3,571 | 1,429 | 04 Mar 2026 | Direct | ||
| Gerardo Hernandez | TMDX | Common Stock | Sale | -33% | $1,065,212 | $147.21 | -7,236 | 14,689 | 04 Mar 2026 | Direct |
| Gerardo Hernandez | TMDX | Common Stock | Options Exercise | 54.1% | 7,236 | 20,601 | 04 Mar 2026 | Direct | ||
| Gerardo Hernandez | TMDX | Stock Option (Right to Buy) | Options Exercise | -64.5% | -7,236 | 3,975 | 04 Mar 2026 | Direct | ||
| Gerardo Hernandez | TMDX | Common Stock | Sale | -2.49% | $52,170 | $139.12 | -375 | 14,689 | 02 Mar 2026 | Direct |
| Anil P. Ranganath | TMDX | Common Stock | Sale | -6.19% | $120,200 | $139.12 | -864 | 13,091 | 02 Mar 2026 | Direct |
| Nicholas Corcoran | TMDX | Common Stock | Sale | -9.04% | $412,630 | $139.12 | -2,966 | 29,831 | 02 Mar 2026 | Direct |
| Giovanni Cecere | TMDX | Common Stock | Award | 139% | 11,082 | 19,057 | 18 Feb 2026 | Direct | ||
| Giovanni Cecere | TMDX | Stock Option (Right to Buy) | Award | 16,734 | 16,734 | 18 Feb 2026 | Direct | |||
| Nicholas Corcoran | TMDX | Common Stock | Tax liability | -2.91% | -984 | 32,797 | 23 Jan 2026 | Direct | ||
| Gerardo Hernandez | TMDX | Common Stock | Sale | -5.76% | $128,450 | $139.62 | -920 | 15,064 | 04 Dec 2025 | Direct |
| David Weill | TMDX | Common Stock | Sale | -29.2% | $693,200 | $138.64 | -5,000 | 12,134 | 03 Dec 2025 | Direct |
| David Weill | TMDX | Common Stock | Options Exercise | 41.2% | 5,000 | 17,134 | 03 Dec 2025 | Direct | ||
| David Weill | TMDX | Stock Option (Right to Buy) | Options Exercise | -50% | -5,000 | 5,000 | 03 Dec 2025 | Direct | ||
| Anil P. Ranganath | TMDX | Common Stock | Sale | -17.7% | $435,660 | $145.22 | -3,000 | 13,955 | 25 Nov 2025 | Direct |
| Anil P. Ranganath | TMDX | Common Stock | Options Exercise | 21.5% | 3,000 | 16,955 | 25 Nov 2025 | Direct | ||
| Anil P. Ranganath | TMDX | Stock Option (Right to Buy) | Options Exercise | -28.8% | -3,000 | 7,420 | 25 Nov 2025 | Direct | ||
| Waleed H. Hassanein | TMDX | Common Stock | Purchase | 1.8% | $1,000,350 | $114.00 | 8,775 | 495,009 | 17 Nov 2025 | By the Waleed H. Hassanein Revocable Trust |
| Edward M. Basile | TMDX | Common Stock | Sale | -59.1% | $540,324 | $130.45 | -4,142 | 2,866 | 29 Oct 2025 | Direct |
| Edward M. Basile | TMDX | Common Stock | Options Exercise | 144.5% | 4,142 | 7,008 | 29 Oct 2025 | Direct | ||
| Edward M. Basile | TMDX | Stock Option (Right to Buy) | Options Exercise | -100% | -4,142 | 0 | 29 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.